Company profile for Surface Oncology

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some pa...
Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors"​, have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
50 Hampshire Street, 8th Floor Cambridge, MA 02139
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com//news-release/2023/08/31/2735679/0/en/Surface-Oncology-Announces-ISS-and-Glass-Lewis-Both-Recommend-Stockholders-Vote-FOR-the-Proposed-Merger-with-Coherus-BioSciences.html

GLOBENEWSWIRE
31 Aug 2023

https://www.globenewswire.com/news-release/2023/08/02/2716699/0/en/Surface-Oncology-Reports-Financial-Results-and-Corporate-Highlights-for-Second-Quarter-2023.html

GLOBENEWSWIRE
02 Aug 2023
Surface warns bankruptcy possible if shareholders reject merger
Surface warns bankruptcy possible if shareholders reject merger

02 Aug 2023

// Nick Paul Taylor FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/surface-warns-bankruptcy-possible-if-shareholders-reject-coherus-merger

Nick Paul Taylor FIERCE BIOTECH
02 Aug 2023

https://www.globenewswire.com/news-release/2023/05/04/2661329/0/en/Surface-Oncology-Reports-Financial-Results-and-Corporate-Highlights-for-First-Quarter-2023.html

GLOBENEWSWIRE
04 May 2023

https://www.globenewswire.com/news-release/2023/04/18/2648805/0/en/Surface-Oncology-Presents-New-Preclinical-Data-on-SRF114-a-fully-human-anti-CCR8-antibody-at-the-AACR-Annual-Meeting-2023.html

GLOBENEWSWIRE
18 Apr 2023

https://www.globenewswire.com/news-release/2023/03/16/2628594/0/en/Surface-Oncology-to-Present-New-Preclinical-SRF114-Data-at-the-American-Association-for-Cancer-Research-AACR-Annual-Meeting-2023.html

GLOBENEWSWIRE
16 Mar 2023

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty